Chemed Corporation (NYSE:CHE) Shares Purchased by Boston Trust Walden Corp

Boston Trust Walden Corp lifted its stake in shares of Chemed Corporation (NYSE:CHE - Free Report) by 1.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 246,351 shares of the company's stock after acquiring an additional 4,179 shares during the period. Chemed accounts for approximately 1.1% of Boston Trust Walden Corp's portfolio, making the stock its 13th biggest holding. Boston Trust Walden Corp owned 1.69% of Chemed worth $151,585,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Whipplewood Advisors LLC boosted its stake in shares of Chemed by 54.5% during the first quarter. Whipplewood Advisors LLC now owns 51 shares of the company's stock valued at $31,000 after acquiring an additional 18 shares during the last quarter. Impact Capital Partners LLC boosted its stake in shares of Chemed by 2.7% during the 1st quarter. Impact Capital Partners LLC now owns 763 shares of the company's stock worth $469,000 after purchasing an additional 20 shares during the last quarter. CIBC Asset Management Inc boosted its position in Chemed by 5.1% during the fourth quarter. CIBC Asset Management Inc now owns 457 shares of the company's stock worth $242,000 after acquiring an additional 22 shares during the last quarter. CBIZ Investment Advisory Services LLC boosted its position in Chemed by 64.7% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 56 shares of the company's stock worth $30,000 after acquiring an additional 22 shares during the last quarter. Finally, CIBC Private Wealth Group LLC boosted its position in Chemed by 13.5% during the fourth quarter. CIBC Private Wealth Group LLC now owns 185 shares of the company's stock worth $98,000 after acquiring an additional 22 shares during the last quarter. Institutional investors and hedge funds own 95.85% of the company's stock.

Chemed Stock Performance

CHE opened at $546.00 on Thursday. The company's 50 day simple moving average is $569.45 and its 200 day simple moving average is $565.09. Chemed Corporation has a 1 year low of $512.12 and a 1 year high of $623.61. The stock has a market capitalization of $7.99 billion, a PE ratio of 26.60, a P/E/G ratio of 2.28 and a beta of 0.54.

Chemed (NYSE:CHE - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The company reported $5.63 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.04. The company had revenue of $646.94 million for the quarter, compared to analyst estimates of $641.78 million. Chemed had a net margin of 12.40% and a return on equity of 27.58%. Chemed's revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter last year, the business earned $5.20 EPS. As a group, sell-side analysts expect that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.

Chemed Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 17th. Stockholders of record on Thursday, May 29th were paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 0.37%. The ex-dividend date of this dividend was Thursday, May 29th. Chemed's dividend payout ratio is currently 9.74%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on CHE shares. Wall Street Zen upgraded Chemed from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Royal Bank Of Canada raised their price target on Chemed from $667.00 to $674.00 and gave the stock an "outperform" rating in a research note on Monday, April 28th.

Insider Activity

In other news, EVP Spencer S. Lee sold 1,500 shares of Chemed stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $577.86, for a total value of $866,790.00. Following the transaction, the executive vice president now directly owns 16,127 shares of the company's stock, valued at $9,319,148.22. The trade was a 8.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Kevin J. Mcnamara sold 1,000 shares of Chemed stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $615.33, for a total transaction of $615,330.00. Following the transaction, the chief executive officer now directly owns 101,679 shares in the company, valued at approximately $62,566,139.07. This trade represents a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,500 shares of company stock valued at $3,213,780 in the last three months. Corporate insiders own 3.29% of the company's stock.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.